What It Is
Retatrutide, also known by its development code LY3437943, is an investigational peptide-class "triple agonist" designed to activate three separate metabolic hormone receptors at once: GIP, GLP-1, and glucagon.[1] Eli Lilly is developing it for obesity, type 2 diabetes, and related metabolic conditions, but it is not an FDA-approved drug and has no approved prescription product on the market.
Retatrutide is often discussed alongside tirzepatide, a dual GIP/GLP-1 agonist, and semaglutide, a GLP-1-only agonist. Unlike those two, retatrutide remains in Phase 3 clinical trials rather than approved labeling, and its results should be read as investigational until regulators complete their review.[2]
How It Works
Retatrutide combines activity at the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) in a single molecule.[10] GLP-1 receptor activity is associated with glucose-dependent insulin release, slowed gastric emptying, and reduced appetite; GIP receptor activity contributes to post-meal insulin response; and glucagon receptor activity — the feature that distinguishes retatrutide from GLP-1-only or dual GIP/GLP-1 drugs — is thought to influence energy expenditure and fat metabolism.[10][11]
This three-pathway design is biologically plausible and consistent with incretin physiology, but mechanism alone does not establish a clinical outcome; that requires trial data.
What the Research Shows
Retatrutide has produced large weight reductions in controlled metabolic trials. In a Phase 2 obesity trial, the highest-dose group had a mean reduction of roughly 24% at 48 weeks.[4] Eli Lilly's May 2026 TRIUMPH-1 topline release reported a mean reduction of about 28% at 80 weeks in the highest-dose efficacy estimand.[7] The Phase 3 result should remain identified as sponsor-reported topline evidence until a complete peer-reviewed report permits independent scrutiny; cross-trial comparisons are also unreliable because designs and populations differ.
Phase 2 and Phase 3 studies in type 2 diabetes reported dose-dependent HbA1c reductions, while a MASLD substudy reported reductions in liver fat.[5][6][8] These are investigational findings, not approved-label outcomes, and long-term cardiovascular and safety endpoints remain under evaluation.
Safety & Side Effects
Reported adverse effects are predominantly gastrointestinal — nausea, diarrhea, vomiting, and constipation — and were more frequent with higher doses or faster escalation in controlled trials.[4][5][8]
Because retatrutide is not FDA-approved, there is no approved label defining contraindications, interactions, manufacturing specifications, or guidance for pregnancy and breastfeeding. Safety concerns sometimes inferred from semaglutide or tirzepatide labels are analogies, not retatrutide-specific instructions.[12][13]
Regulatory Status
Retatrutide is investigational only. FDA states that it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.[3] Phase 3 trials continue, and a sponsor press release or trial-registry entry is not regulatory approval.
FDA also states that retatrutide cannot be used in compounding under federal law and warns that unapproved GLP-1-class products sold online are not equivalent to reviewed pharmaceuticals.[3] A product sold today as a retatrutide "research vial" is not the investigational product supplied under a controlled clinical-trial protocol and has no FDA-reviewed manufacturing quality, purity, or dosing accuracy.
Retatrutide vs. Approved Incretin Therapies
Semaglutide and tirzepatide have FDA-approved products, while retatrutide remains investigational.[12][13] Retatrutide's added glucagon-receptor activity separates it mechanistically, but apparent differences in weight loss across separate trials do not establish comparative superiority. A registered head-to-head Phase 3 trial against tirzepatide is underway.[15] Until those results are complete, retatrutide's efficacy signals must be weighed against its earlier regulatory stage and smaller safety database.